Enabling Next-Generation Biotherapeutics
Making innovative biotherapeutics available for patients in need.Perspix Biotech is creating next-generation biotherapeutics for patients with cancer by leapfrogging traditional drug discovery and development approaches. We aim to radically accelerate the technical development of next-generation biological drug modalities through a truly digitally transformed discovery platform. This will significantly reduce development times and costs – making innovative biotherapeutics available for patients in need.
Focus on multi-specific antibodies
The roPROTix platform: Creating a digital to physical continuum for efficient multi-targeting drug discovery
At Perspix Biotech, we are shifting the paradigm of multi-targeting drug discovery by connecting “digital design” and “physical” experimentation workflows into a closed-loop-feedback-system.
Our path to multi-targeting biotherapeutics with game-changing properties
Perspix Biotech is aiming at building an innovative portfolio of internal and partnered programs in oncology, focusing on novel target combinations with strong clinical evidence for which no solutions exist.
Committed to enabling the next generation of biological cancer drugs
Enabling Next-Generation Biotherapeutics
Making innovative biotherapeutics available for patients in need.Perspix Biotech is creating next-generation biotherapeutics for patients with cancer by leapfrogging traditional drug discovery and development approaches. We aim to radically accelerate the technical development of next-generation biological drug modalities through a truly digitally transformed discovery platform. This will significantly reduce development times and costs – making innovative biotherapeutics available for patients in need.
Focus on multi-specific antibodies
Multi-specific antibody therapeutics are emerging as powerful treatment options for complex, multifactorial illnesses in particular cancer. They are engineered to combine the functional activities of two or more monoclonal antibodies (mAbs) into one molecule to address multiple disease targets simultaneously.
The roPROTix platform: Creating a digital to physical continuum for efficient multi-targeting drug discovery
At Perspix Biotech, we are shifting the paradigm of multi-targeting drug discovery by connecting “digital design” and “physical” experimentation workflows into a closed-loop-feedback-system.
Our path to multi-targeting biotherapeutics with game-changing properties
Perspix Biotech is aiming at building an innovative portfolio of internal and partnered programs in oncology, focusing on novel target combinations with strong clinical evidence for which no solutions exist.
Committed to enabling the next generation of biological cancer drugs
At Perspix Biotech we bring together proven specialists from areas of digital technology integration and biological drug development with renowned company builders and commercial experts.
Now it is time for change
Copyright 2022 Perspix Biotech | All rights reserved
Copyright 2022 Perspix Biotech | All rights reserved